Diamond-Blackfan Anemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Diamond-Blackfan anemia (DBA) is a rare inherited disorder that affects the body's production of red blood cells. It typically appears in infancy and is characterized by anemia, which can cause symptoms such as paleness, difficulty feeding, and failure to thrive. About 50% of cases of DBA are caused by mutations in specific genes that produce ribosomal proteins S19, L5, L11 OR S26, while mutations in other genes, such as S7, S24, S17, and S10, cause a small percentage. In addition to anemia, around 50% of patients with DBA also have congenital malformations, and a higher rate may have premature birth (20%), low birth weight (28%), and growth delays (22%). Most cases are diagnosed in the first few years of life, with 95% diagnosed before age two and almost 99% before age 5. However, DBA can sometimes be present at birth or detected during pregnancy. It is important to distinguish DBA from other types of anemia, such as those caused by viral infections or temporary conditions in children. People with DBA are at increased risk of developing certain blood disorders, such as acute myeloid leukemia, myelodysplastic syndrome, solid tumors, complications related to iron overload, chronic steroid use, organ failure, growth failure and HSCT.

·       Diamond Blackfan anemia is a sporadic disease with an incidence rate of 1 in 500000 live births.

Thelansis’s “Diamond-Blackfan Anemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diamond-Blackfan Anemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Diamond-Blackfan Anemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Diamond-Blackfan Anemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Diamond-Blackfan Anemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033